<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[barr Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/barr.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to barr]]></description>
	<s:counts start="0" returned="2" found="2" />
	<language>en-us</language>
	<item>
		<title><![CDATA[The Pfizer-Shire Deal Worst-Case Scenario]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000569/the-pfizer-shire-deal-worst-case-scenario/]]></link>
		<description><![CDATA[Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 Jan 2009 14:00:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/medicaid.html"><![CDATA[Medicaid]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/adhd.html"><![CDATA[ADHD]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/barr.html"><![CDATA[Barr]]></category>
		<category domain="http://resources.bnet.com/topic/cola.html"><![CDATA[Cola]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Medicis Solves One Solodyn Problem But Barr Pops Up With Another]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000544/medicis-solves-one-solodyn-problem-but-barr-pops-up-with-another/]]></link>
		<description><![CDATA[Barr Pharmaceuticals has filed to make a generic version of Medicis's acne drug, Solodyn. Medicis stock had received a nice boost at the beginning of December when it announced an unexpected deal with a different company, Impax, over generic versions of Solodyn.    The deal meant Medicis would...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 30 Dec 2008 12:08:26 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/medicis.html"><![CDATA[Medicis]]></category>
		<category domain="http://resources.bnet.com/topic/barr.html"><![CDATA[Barr]]></category>
		<category domain="http://resources.bnet.com/topic/solodyn.html"><![CDATA[Solodyn]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
</channel>
</rss>
